Press "Enter" to skip to content

Talazoparib in Advanced HER2-Negative Breast Cancer and Other Solid Tumors Lacking BRCA1/2 Mutations – Cancer Therapy Advisor

admin 0

Talazoparib in Advanced HER2-Negative Breast Cancer and Other Solid Tumors Lacking BRCA1/2 Mutations  Cancer Therapy Advisor

At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, researchers presented phase 2 data on the activity of the PARP inhibitor talazoparib …

“breast cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *